Literature DB >> 20596676

Y-box binding protein 1 is up-regulated in proliferative breast cancer and its inhibition deregulates the cell cycle.

Ying-Nan Yu1, George Wai-Cheong Yip, Puay-Hoon Tan, Aye Aye Thike, Ken Matsumoto, Masafumi Tsujimoto, Boon-Huat Bay.   

Abstract

The Y-box-binding protein 1 (YB-1), a member of the cold-shock domain RNA-and DNA-binding protein family, has pleiotropic functions such as regulation of the cell cycle. The aim of this study was to evaluate if YB-1 is a proliferative marker in breast cancer and elucidate potential downstream targets involved in YB-1-mediated cell cycle regulation using RNA interference technology. YB-1 protein expression was evaluated in tissue microarrays of 131 breast invasive ductal carcinomas by immunohistochemistry, while the YB-1 gene expression profile was evaluated in the T-47D, MDA-MB-231, ZR-75-1 and MCF7 breast cancer cell lines. Silencing of the YB-1 gene in T-47D breast cancer cells was performed using siRNA and the effects of down-regulation of YB-1 on cell growth and regulation of the cell cycle were ascertained. A focused panel of 84 genes involved in cell cycle progression was also examined. In tissue microarrays, YB-1 expression was shown to be associated with proliferating cell nuclear antigen (PCNA) immunostaining. siRNA-mediated silencing of the YB-1 gene inhibited cell proliferation and induced G1 phase cell cycle arrest in T-47D breast cancer cells. Knockdown of the YB-1 gene induced up-regulation of two genes which contribute to G1-arrest (RAD9A and CDKN3 genes) and down-regulation of ten genes associated with positive regulation of the cell cycle (SKP2, SUMO1, ANAPC4, CCNB1, CKS2, MNAT1, CDC20, RBBP8, KPNA2 and CCNC genes). The data obtained from the tissue microarrays and cell lines provide evidence that YB-1 is a reliable marker of cell proliferation and possibly a potential molecular target in breast cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20596676

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  15 in total

1.  YB-1, the E2F pathway, and regulation of tumor cell growth.

Authors:  Annette Lasham; Weini Samuel; Helen Cao; Rachna Patel; Reena Mehta; J Lewis Stern; Glen Reid; Adele G Woolley; Lance D Miller; Michael A Black; Andrew N Shelling; Cristin G Print; Antony W Braithwaite
Journal:  J Natl Cancer Inst       Date:  2011-12-28       Impact factor: 13.506

2.  De-regulation of the RBBP6 isoform 3/DWNN in human cancers.

Authors:  Zukile Mbita; Mervin Meyer; Amanda Skepu; Margot Hosie; Jasper Rees; Zodwa Dlamini
Journal:  Mol Cell Biochem       Date:  2011-12-03       Impact factor: 3.396

3.  CKS2 in human cancers: Clinical roles and current perspectives (Review).

Authors:  Hanyu You; Huayue Lin; Zhongying Zhang
Journal:  Mol Clin Oncol       Date:  2015-02-04

4.  KIF21A regulates breast cancer aggressiveness and is prognostic of patient survival and tumor recurrence.

Authors:  Anton J Lucanus; Aye Aye Thike; Xing Fei Tan; Kee Wah Lee; Shiyuan Guo; Victoria P C King; Von Bing Yap; Boon Huat Bay; Puay Hoon Tan; George W Yip
Journal:  Breast Cancer Res Treat       Date:  2021-10-26       Impact factor: 4.872

5.  YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification.

Authors:  A H Davies; I Barrett; M R Pambid; K Hu; A L Stratford; S Freeman; I M Berquin; S Pelech; P Hieter; C Maxwell; S E Dunn
Journal:  Oncogene       Date:  2011-03-21       Impact factor: 9.867

6.  Impact of oncogenic K-RAS on YB-1 phosphorylation induced by ionizing radiation.

Authors:  Mahmoud Toulany; Tim-Andre Schickfluss; Wolfgang Eicheler; Rainer Kehlbach; Birgit Schittek; H Peter Rodemann
Journal:  Breast Cancer Res       Date:  2011-03-10       Impact factor: 6.466

7.  Identifying CDKN3 Gene Expression as a Prognostic Biomarker in Lung Adenocarcinoma via Meta-analysis.

Authors:  Xiao Zang; Min Chen; Yunyun Zhou; Guanghua Xiao; Yang Xie; Xinlei Wang
Journal:  Cancer Inform       Date:  2015-05-24

8.  The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.

Authors:  Heloisa Helena Milioli; Renato Vimieiro; Carlos Riveros; Inna Tishchenko; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

9.  Prognostic significance of phosphoglycerate dehydrogenase in breast cancer.

Authors:  Muthukrishnan Chandrika; Pei Jou Chua; Umamaheswari Muniasamy; Ruby Yun Ju Huang; Aye Aye Thike; Cheng Teng Ng; Puay Hoon Tan; George W Yip; Boon Huat Bay
Journal:  Breast Cancer Res Treat       Date:  2021-02-24       Impact factor: 4.872

10.  Silencing cyclin-dependent kinase inhibitor 3 inhibits the migration of breast cancer cell lines.

Authors:  Miao Deng; Jianguang Wang; Yanbin Chen; Like Zhang; Gangqiang Xie; Qipeng Liu; Ting Zhang; Pengfei Yuan; Dechun Liu
Journal:  Mol Med Rep       Date:  2016-06-14       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.